Addition of Continuous Cardiac Output measurements to improve care of chronic cardiac patients at home

PCV aims to revolutionize chronic-disease-management by enhancing the quality-of-patient-information sent automatically to cardiologists, thereby reducing their workload and improving care for the growing population of patients with chronic cardiovascular conditions. This will improve diagnostic accuracy, reduce the frequency of clinical interventions, and significantly lower healthcare costs. PCV's PULSENSE system, which provides continuous, 24/7 at-home monitoring of Pulmonary Artery Pressure (PAP) and patient activity is being developed under the BMC\#10101664 grant. This 12-month industrial research project leverages real-world in-hospital data from the ASPIRE library to develop and optimize a calibrated algorithm that can derive Cardiac Output (CO) measurements from the PULSENSE data. Many research efforts have focused on algorithms that interpret brief invasive PAP measurements taken during hospital visits, achieving limited accuracy within that environment. However, PCV's PULSENSE system offers the unique ability to continuously measure PAP, CO, and patient activity in an at-home setting, providing cardiologists with the most comprehensive haemodynamic dataset available. In contrast, the competitive CardioMEMS system relies on once-daily spot PAP measurements, which do not capture dynamic patient responses to activities, stress, or lifestyle factors. By validating and optimising a continuous CO algorithm for PULSENSE, PCV aims to deliver real-time, actionable insights that extend beyond what current solutions like CardioMEMS offer. This will enable cardiologists to assess new dimensions of cardiac performance---such as "resilience," "responsiveness," and "recovery"---providing a deeper understanding of patient stability. The BMC funding allows PCV's data science team to extract features from the ASPIRE library, develop AI model and fine-tune it to ensure the derived CO data aligns with measured CO values over time. As part of the pre-clinical phase, an individualized calibration constant will be established during device implantation, ensuring precise, patient specific CO tracking. The algorithm's performance will be evaluated through a series of pre-clinical studies already included in the \#10101664 program. Inclusion of continuous CO-data and automated analysis within PULSENSE reports will provide cardiologists with robust, real-time insights for automated triage and alert systems, ensuring that critical patients receive immediate attention. This approach will eliminate unnecessary clinic visits and reduce clinician burden. By combining continuous PAP and CO monitoring with automated analysis, the automated insights provided by the system will empower clinicians with comprehensive patient data, surpassing the capabilities of competitors like CardioMEMS. Through precision-monitoring and personalized care, PCV is set to redefine chronic disease management, ensuring better patient outcomes while reducing the overall burden on healthcare systems.